MedMira Inc. (FRA:47M)

Market Cap	30.31M -21.5%
Revenue (ttm)	144.15K -34.6%
Net Income	-2.50M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	826
Open	0.0370
Previous Close	0.0345
Day's Range	0.0370 - 0.0370
52-Week Range	0.0265 - 0.0690
Beta	n/a
RSI	50.68
Earnings Date	Apr 2, 2026

About MedMira

MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1993
• Employees: 52
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 47M

Financial Performance

In fiscal year 2025, MedMira's revenue was 240,509, a decrease of -41.70% compared to the previous year's 412,568. Losses were -4.52 million, 36.0% more than in 2024.

Financial numbers in CAD